Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

A new AI model has become so good at predicting how molecules evolve over time that, in the future, it could speed up the ...

Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion valuation, and more.

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...

Building on its legacy of standardizing LC separation, Evosep now extends upstream to sample preparation, delivering complete ...

Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...